DUBLIN--(BUSINESS WIRE)--Mallinckrodt plc (NYSE: MNK), a global specialty pharmaceutical and global medical imaging company, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2014. Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, will represent the company in a session scheduled to begin at 2:30pm PST (5:30pm EST).
Individuals who are unable to attend the meeting in person will be able to view a live video and webcast at: http://mallinckrodt.com/investor_relations. A replay will be available on the website following the conclusion of the meeting.
Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and a commercial presence in roughly 70 countries. The company’s fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.